Clinical Trial Update: Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 pivotal study is planned to compare YL202 against Docetaxel in patients with EGFR-sensitive, non-squamous non-small cell lung cancer; the trial is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• YL202

Snippet

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING